NXTC Nasdaq

NextCure, Inc.

NXTC | $1.43 -6.54% -6.99% 180K

(0.0% 1d) (-23.1% 1m) (0.7% 1y) (0.0% 2d) (-5.0% 3d) (-4.4% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 39,901,329
http://www.nextcure.com
Sec Filling | Patents | 69 employees

(US) NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

cancer

add to watch list Paper trade email alert is off

Press-releases

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| Email alert Add to watchlist
nc410 asco

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| -28.84% | O: 0.93% H: 1.38% C: -5.53%
drug antibody preclinical

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| -5.14% | O: -1.51% H: 0.0% C: 0.0%
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| -36.25% | O: -4.17% H: 8.26% C: -6.09%

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| -27.83% | O: 2.83% H: 17.89% C: 14.22%
conference

NextCure Provides Business Update and Reports Full Year 2023 Financial Results
Published: 2024-03-21 (Crawled : 13:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| 8.51% | O: 1.42% H: 30.07% C: 17.48%
business year update financial results

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| -19.9% | O: -5.76% H: 7.22% C: 5.56%
cell preclinical

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| 33.04% | O: -1.74% H: 4.42% C: 0.0%
candidate disorders treatment preclinical

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| 34.21% | O: -1.75% H: 2.68% C: 0.0%
treatment bone

NextCure Provides Year-End Clinical Pipeline Updates
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| 5.52% | O: -26.21% H: 11.21% C: 9.35%
pipeline

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
Published: 2023-11-20 (Crawled : 12:00) - globenewswire.com
NXTC | $1.43 -6.54% -6.99% 180K

Health Technology

| 19.53% | O: 1.56% H: 0.0% C: -4.62%
conference

See all